EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.

@article{MartnezMartn2015EuroInfAM,
  title={EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.},
  author={Pablo Mart{\'i}nez-Mart{\'i}n and Prashanth Reddy and Regina Katzenschlager and Angelo Antonini and Antoniya Todorova and P Odin and Tove Henriksen and Anne J Martin and Daniela Calandrella and Alexandra Rizos and Narissah Bryndum and Arne Glad and Haidar S Dafsari and Lars Timmermann and Georg Ebersbach and Milica Gregoric Kramberger and Michael Samuel and Karoline Wenzel and Volker Tomantschger and Alexander Storch and Heinz Reichmann and Zvezdan Pirtosek and Maja Tro{\vs}t and Per Svenningsson and Sven E. P{\aa}lhagen and Jens Volkmann and Kallol Ray Chaudhuri},
  journal={Movement disorders : official journal of the Movement Disorder Society},
  year={2015},
  volume={30 4},
  pages={510-6}
}
Subcutaneous apomorphine infusion (Apo) and intrajejunal levodopa infusion (IJLI) are two treatment options for patients with advanced Parkinson's disease (PD) and refractory motor complications, with varying cost of treatment. There are no multicenter studies comparing the effects of the two strategies. This open-label, prospective, observational, 6-month… CONTINUE READING